Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly’s push into gene editing for cardiovascular conditions and signals renewed confidence in the sector. The all-cash tender offer values Verve at $10.50 per share upfront. That’s a 113% premium over the company’s 30-day volume-weighted average price plus a $3 contingent value right tied to starting phase 3 trials for its lead program. The deal comes as Verve’s VERVE-102 showed clean safety data in early testing, earned FDA Fast Track status, and overcame prior setbacks, while gene editing firms grapple with funding shortages and safety worries.
The acquisition marks something of a shift for Lilly, which has tended to build gene editing capabilities through partnerships rather than internal development. Since 2020, Lilly has invested in collaborations with Precision BioSciences (ARCUS technology), Scribe Therapeutics (CRISPR XE), and struck deals with Verve and Beam Therapeutics
The seven-year journey from tragedy to breakthrough
Verve Therapeutics traces its origins to a personal tragedy. Dr. Sekar Kathiresan, a Harvard cardiologist and human geneticist, founded the company in 2018 after his brother Senthil died from a heart attack at age 42. Kathiresan shifted his career to focus on one-time genetic treatments for cardiovascular disease, the same condition that ravaged his family. Verve’s core technology uses base editing to make precise DNA changes. This inactivates genes tied to high cholesterol and mimics rare protective mutations in humans.
The road to acquisition demanded major scientific shifts and key partnerships. Verve launched its IPO in 2021 at $19 per share. It raised $267 million in the upsized offering, one of the year’s biggest biotech debuts. Shares later climbed past $70 amid a gene therapy surge. But challenges mounted in 2024. Verve’s lead program, VERVE-101, hit a wall in early trials. One patient developed elevated liver enzymes and low platelet counts, prompting a voluntary enrollment pause. The issues resolved without lasting harm. Still, the halt overshadowed strong efficacy signals, including up to 73% LDL cholesterol cuts in some participants.
Verve swiftly pivoted to VERVE-102. This next-generation candidate swapped in a new lipid nanoparticle with GalNAc conjugation for sharper liver targeting. The move proved pivotal. Initial Phase 1b data from the Heart-2 trial, released April 14, 2025, showed dose-dependent LDL-C cuts. At the highest dose, patients saw a mean 53% reduction, with one hitting 69%, and no treatment-related serious adverse events. The clean safety profile addressed VERVE-101’s prior issues. It reaffirmed base editing’s potential and cleared the path for Lilly’s acquisition.
Analysts split on strategic value despite “bargain” pricing
Investment analysts offered divergent views on the deal’s merits, though most acknowledged Lilly secured favorable terms. William Blair’s Myles Minter called it an outright “bargain,” noting his pre-deal fair value estimate of $30.86 per share versus the $10.50 offer price. “The 115% premium is still a win for Verve shareholders and the gene editing space more broadly, which has been under significant macro pressure,” Minter stated, predicting the CVR would likely pay out with Phase 3 initiation possible by first half 2027.
BMO Capital Markets struck a more skeptical tone, with analyst Kostas Biliouris questioning the commercial rationale. BMO assigned only a 70% probability to the CVR payout and suggested Lilly might find better uses for its capital, though acknowledging the deal size was modest relative to Lilly’s investment capacity.
The CVR structure itself drew significant attention, with analysts noting that at a 5% discount rate, the $3.00 contingent payment had a present value of approximately $1.75. The market’s initial pricing of Verve shares around $11.12 suggested investors assigned roughly a 21% probability to achieving the Phase 3 milestone within the 10-year window.
Gene editing stocks surge as sector finds validation
Analysts split on the deal’s value, though most agreed Lilly got it cheap. William Blair’s Myles Minter labeled it a “bargain.” He pegged Verve’s pre-deal fair value at $30.86 per share, considerably above the $10.50 upfront offer. The 115% premium helps Verve shareholders, Minter said, and lifts the gene-editing sector amid tough market conditions. He expects the CVR to trigger, with Phase 3 possible by early 2027.
BMO Capital Markets took a cautious stance. Analyst Kostas Biliouris doubted the need for more genetic drugs in this space. His team gave the CVR just a 70% shot at paying out by around 2028. Lilly could deploy its cash elsewhere, BMO noted, but the deal’s scale stays small against the pharma giant’s resources.
The CVR drew close scrutiny. Analysts calculated its $3.00 payout at a present value of about $1.75 using a 5% discount rate. Early trading pushed Verve shares to around $11.12. That implied investors saw only a 21% chance of hitting the Phase 3 milestone in 10 years.
Cardiologists embrace paradigm shift while competitors watch closely
The medical community has embraced the potential shift. Dr. Andrew M. Bellinger, who presented VERVE-101 trial data at the American Heart Association Scientific Sessions 2023, emphasized: “Instead of daily pills or intermittent injections over decades to lower bad cholesterol, this study reveals the potential for a new treatment option – a single-course therapy that may lead to deep LDL-C lowering for decades.” The one-time treatment approach addresses a common challenge: studies show significant numbers of patients discontinue LDL-lowering therapy, with adherence remaining a major barrier to effective cardiovascular disease management.
“Lilly shares our vision,” CEO Sekar Kathiresan stated, “and we believe their global research, clinical, regulatory and commercial capabilities will help accelerate the development of our medicines.” Kathiresan has committed to tender his shares, along with other major stakeholders including Andrew Ashe and entities affiliated with GV, representing 17.8% of outstanding shares.
The deal, pending customary approvals, is expected to close in Q3 2025.
Filed Under: Cell & gene therapy
